SEMA

Semaglutide

Primary Function: Appetite regulation, glucose control, and weight management
Research Use: Obesity studies, type 2 diabetes, metabolic syndrome models
Molecular Formula: C187H291N45O59
CAS Number: 910463-68-2
Synonyms: Ozempic, Wegovy, Rybelsus

Description:
Semaglutide is a long-acting GLP-1 receptor agonist that mimics the activity of glucagon-like peptide-1, a key hormone in regulating insulin, satiety, and blood sugar levels. It has been extensively studied for its potent effects on weight reduction, glycemic control, and cardiovascular protection. Its ability to reduce appetite, delay gastric emptying, and improve insulin sensitivity makes it one of the most researched compounds in obesity and type 2 diabetes treatment models.

Mechanism of Action:

• Activates GLP-1 receptors in the pancreas and hypothalamus
• Enhances glucose-dependent insulin secretion
• Suppresses glucagon release
• Delays gastric emptying and reduces appetite

Key Research Areas:

• Obesity and appetite suppression
• Type 2 diabetes and insulin resistance
• Cardiovascular risk reduction
• Liver fat reduction and metabolic flexibility

History of Discovery:
Semaglutide was developed by Novo Nordisk and approved by the FDA in 2017 for the treatment of type 2 diabetes. It was later approved in 2021 for chronic weight management under the trade name Wegovy. The peptide was engineered as a longer-lasting and more potent GLP-1 analog than its predecessor, Liraglutide, with a half-life of approximately one week.

Case Studies:

1. Weight Loss in Obese Adults (2021, STEP 1 Trial – NEJM): Participants using Semaglutide lost an average of 14.9% of body weight over 68 weeks, significantly more than placebo. [N Engl J Med. 2021;384:989–1002.]
2. Cardiovascular Risk Reduction in Diabetics (2016, SUSTAIN-6 Trial): Semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 26% in patients with type 2 diabetes. [N Engl J Med. 2016;375:1834–1844.]
3. Improved Liver Health and Insulin Sensitivity (2020, Lancet Gastroenterol Hepatol): In non-alcoholic fatty liver disease (NAFLD) models, Semaglutide significantly reduced liver inflammation and fat accumulation. [Lancet Gastroenterol Hepatol. 2020;5(4):362–373.]

Packaging Information:

• Form: Lyophilized powder or sterile solution
• Purity: ≥ 99%
• For research use only. Not for human or veterinary use.